Dazukibart clinical trials
Also written PF-06823859.
How each study uses dazukibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dazukibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses dazukibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]RecruitingPhase 3PfizerNCT05895786Written as PF-06823859
- A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory MyopathiesRecruitingPhase 3PfizerNCT06698796Written as Dazukibart
- A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.TerminatedPhase 2PfizerNCT05879718Written as PF-06823859
- An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent StudyCompletedPhase 2PfizerNCT05192200Written as Anti-Beta Interferon (PF-06823859)
- Investigation of Safety, Tolerability, Immunogenicity and Pharmacokinetics of Single-Dose of PF-06823859 in Japanese Healthy ParticipantsCompletedPhase 1PfizerNCT05037409Written as PF-06823859
- A Study In Adults With Moderate To Severe DermatomyositisCompletedPhase 2PfizerNCT03181893Written as PF-06823859 low
- Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859CompletedPhase 1PfizerNCT02766621Written as PF-06823859
Codes
What other systems call dazukibart · ClinicalTrials.gg INT017000
- UNII (FDA) K2Q0JXS9B4DAZUKIBARTOne source FDA
- NCI Thesaurus C191872DazukibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | K2Q0JXS9B4 | DAZUKIBART | One source FDA |
| NCI Thesaurus | C191872 | Dazukibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.